Seeing exercise as a punishment for overeating, as opposed to a way to support your wellbeing, is also a part of this
Many people expect rapid, dramatic weight loss
Through systematic analysis of clinical trials, meta-analyses, and emerging evidence from landmark studies like SELECT, this paper evaluates whether GLP-1 agonists represent a transformative breakthrough or an overhyped intervention with significant limitations
The authors note that semaglutide had a holistic therapeutic approach to both liver disease and associated cardiometabolic illnesses. These results lend further credence that semaglutide is the Swiss army knife of medicine we have been looking for, to treat obesity, cardiovascular disease, type 2 diabetes, and now MASH, Beverly Tchang, MD, an endocrinologist and assistant professor of clinical medicine at Weill Cornell Medicine, not affiliated with the trial, told Healthline.
Medical Disclaimer: This article is for informational purposes only and is not medical advice
Buyer Takeaway: FeelGood's value proposition is real: clinician-supervised access to compounded GLP-1 through a platform designed around digital convenience, without insurance requirements or office visits